Study Summary
This trial will explore whether effervescent calcium magnesium citrate (EffCaMgCit) can help people with end stage renal disease on hemodialysis by reducing the formation of calciprotein particles (CPP), which can cause heart and artery problems.
- Chronic Kidney Disease Stage 5
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 3 Secondary · Reporting Duration: 24 months
Trial Safety
Safety Progress
Trial Design
2 Treatment Groups
CaAcS
1 of 2
EffCaMgCit
1 of 2
Active Control
Experimental Treatment
243 Total Participants · 2 Treatment Groups
Primary Treatment: EffCaMgCit · No Placebo Group · Phase 2 & 3
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18 - 99 · All Participants · 3 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Are there still opportunities to enroll in this research project?
"Yes, this study is still looking for participants and was most recently updated on February 9th, 2022. The original posting date was January 22nd, 2017." - Anonymous Online Contributor
Does this research only include young adults in their twenties?
"To be eligible for this particular trial, patients must be between 18-99 years old. However, there are other ongoing trials for patients that are under 18 and ones for patients that are over 65." - Anonymous Online Contributor
How many research subjects are involved in this trial?
"Yes, the trial is still recruiting patients according to the information on clinicaltrials.gov. This specific study was first posted on 1/22/2017 and was edited on 2/9/2022. The research team is looking for 225 individuals total from 1 site." - Anonymous Online Contributor
What are the requirements to sign up for this clinical trial?
"This study is currently enrolling 225 patients with chronic kidney disease. To be eligible, patients must be between 18 and 99 years old. In addition, the following criteria must be met: Adult subjects (> 21 years of age, any cause of CKD) of either gender of any ethnicity with CKD Stage V on hemodialysis will be recruited. Patients with Type II diabetes and hypertension will be allowed. Treatment with drugs for management of osteoporosis (bisphosphonate, teriparatide, or denosumab) or for chronic kidney disease, customary drugs for hypertension or diabetes, and exogenous estrogen or" - Anonymous Online Contributor